Pharmosa Biopharm announced yesterday the successful initial shipment of L606—indicated for pulmonary hypertension associated with interstitial lung disease (PH-ILD)——to its licensing partner, Liquidia. This shipment facilitates the launch of a global, multi-center Phase 3 clinical trial, with patient enrollment expected to begin in 2026.

Clinical and Strategic Value:

• Unmet Medical Needs: L606 is a next-generation inhaled prostacyclin therapy. At its R&D Day and the Jefferies Global Healthcare Conference in London, Liquidia highlighted L606’s core advantages: twice-daily dosing for 24-hour efficacy, superior tolerability, and a reduction in clinical "pain points" such as cough and throat irritation.
• Expanding Indications: Liquidia is broadening the L606 pipeline beyond PAH and PH-ILD to include idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and PH associated with chronic obstructive pulmonary disease (PH-COPD).
• Market Potential: The global target market for PAH and PH-ILD exceeds US$6 billion. With the inclusion of IPF (a US$4 billion market) and other fibrotic lung diseases, the total addressable market is projected to surpass **US$10 billion (NT$300 billion)**.

Resource: 國邑 L606 全球三期臨床全面啟動 優異數據加速雙適應症拚取證